First Tennessee Plaza, 800 S. Gay Street, Suite 1100, Knoxville, TN 37929

Dangerous Prescription Drugs

blog text handwritten

FDA Confirms Actos Link to Bladder Cancer

The U.S. Food and Drug Administration (FDA) issued a public warning on Dec. 12, 2016 confirming that type 2 diabetes medications containing pioglitazone may be linked to an increased risk of bladder cancer. Pioglitazone is a drug used to improve blood… Read More

Study Reveals Risk of Heart Attack Increases with Use of Heartburn Medications

A new study has revealed that proton-pump inhibitors (PPI), used to treat heartburn, could increase the risk of a heart attack. Proton-pump inhibitors, such as Prilosec and Prevacid, are among some of the most widely prescribed drugs. If you or someone… Read More

Takeda Agrees to Pay $2.4 Billion to Settle Actos Bladder Cancer Lawsuits

Following claims it hid the cancer risks of its Actos diabetes medication, Takeda, Japans biggest drug company by revenue, faces product liability lawsuits in the U.S. that involve about 9,000 people. In an effort to settle those lawsuits with thousands… Read More

Takeda Offers $2.2 Billion to Settle Actos Lawsuits

Actos is a drug produced by Takeda, a Japanese pharmaceutical company. Recently, Takeda has offered to settle more than 8,000 lawsuits involving Actos, its flagship diabetes drug. Actos increases a patient's sensitivity to insulin and helps patients… Read More

Teeth Numbing Gels Cause Severe Injuries

The Food and Drug Administration (FDA) issued a strong warning in a safety announcement against the use of gum numbing gels for infant children.  The FDA has found that the use of gum numbing gels containing ingredients such as viscous lidocaine can… Read More

FDA Investigates Benefits of Testosterone Therapy

There are increasing concerns about the safety and effectiveness of testosterone replacement therapy (TRT).  Lawyers and law firms have begun to investigate potential individual and class action lawsuits. Testosterone is a hormone that helps maintain… Read More

back to top